Remove Cardiovascular Disease Remove Coronary Artery Disease Remove Peripheral Arterial Disease
article thumbnail

Chronic exposure to lead, cadmium and arsenic increases risk of cardiovascular disease

Science Daily - Stroke

Around the world, most people are regularly exposed to low or moderate levels of lead, cadmium and arsenic in the environment, increasing risk of coronary artery disease, stroke and peripheral artery disease, according to a new statement.

article thumbnail

Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan area of Brandenburg, Germany

Frontiers in Cardiovascular Medicine

Background and aims In the non-metropolitan region of Brandenburg (Germany), which is characterized by high rates of cardiovascular diseases and underserved medical care, there is a lack of awareness regarding lipoprotein(a) [Lp(a)] as a risk factor. 3.95, p  = 0.003). 3.95, p  = 0.003). vs. 45.8%; 17.6% vs. 13.9%, p  = 0.001).

article thumbnail

Scientists find cancer-like features in atherosclerosis, spurring opportunity for new treatment approaches

Science Daily - Heart Disease

Atherosclerosis is characterized by a narrowing of arterial walls and can increase risk of coronary artery disease, stroke, peripheral artery disease, or kidney disorders.

article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.

article thumbnail

Epidemiology of atherosclerotic cardiovascular disease in polygenic hypercholesterolemia with or without high lipoprotein(a) levels

Frontiers in Cardiovascular Medicine

Background and aims Epidemiology of atherosclerotic cardiovascular disease might be different in patients with polygenic hypercholesterolemia plus high levels (≥30 mg/dl) of Lp(a) (H-Lpa) than in those with polygenic hypercholesterolemia alone (H-LDL).

article thumbnail

Generalisability of trials on antithrombotic treatment intensification in patients with cardiovascular disease

Heart BMJ

Objective Assessment of generalisability of guideline-informing trials on antithrombotic treatment intensification to real-world patients with cardiovascular disease (CVD). Eligible and ineligible patients were compared on baseline characteristics, cardiovascular events, major bleeding and mortality.

article thumbnail

Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis

Circulation

Using mediation Mendelian randomization, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease.